Fig. 4From: Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in KoreaOverall survival by immune checkpoint inhibitors according to previous radiotherapy treatment (a) and type of PD-1 inhibitor (b) in patients with head and neck cancerBack to article page